Epigenetic Regulation of Cancer in Response to Chemotherapy
Free Global Shipping
No minimum orderDescription
Epigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting chapters on timely topics, including Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in Cancer, A Role for the Epigenome in Cancer Cell Drug Tolerance, Histone Methylation and X Chromosomal Genes in Metastasis of Breast Cancer, Targeting Epigenetic Regulation Using Small Molecule Inhibitors, Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung Cancer, From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia), and more. Additional chapters cover Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning, and Knowledge-Based Methods, Probing on the Mechanisms of lncRNAs on Cancer Drug Resistance, Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic Perspectives, and much more.
Key Features
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Cancer Research series
- Includes the latest information on the Epigenetic Regulation of Cancer in Response to Chemotherapy
Readership
Researchers and students
Table of Contents
- 1. Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in Cancer
Katherine Chiappinelli
2. A Role for the Epigenome in Cancer Cell Drug Tolerance
Marie Classon
3. Histone Methylation and X Chromosomal Genes in Metastasis of Breast Cancer
Fei Chen
4. Targeting Epigenetic Regulation Using Small Molecule Inhibitors
Paul B. Fisher
5. Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung Cancer
Shabir Ahmad Ganai
6. From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia)
Wei-Jun Yang and Chris Wood
7. Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning-, and Knowledge-Based Methods
Manny Bacolod
8. Probing on the Mechanisms of lncRNAs on Cancer Drug Resistance
Chandrima Das
9. Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic Perspectives
Xia Weiwei
10. Epigenetic Adaptations in Drug-Tolerant Tumor Cells
Shibasish Chowdhury
11. A Role for Epigenetics in the Recovery from Chemotherapy Exposure
Joseph Landry
12. Reprogramming the Cancer Epigenome - Synergistic Therapy with Epigenetic Drugs
Vijayalakshmi Mahadevan
13. Targeting the Super Elongation Complex for Oncogenic Transcription Driven Tumor Malignancies: Progress in Structure, Mechanisms and Small Molecular Inhibitor Discovery
Kehao Zhao
Product details
- No. of pages: 438
- Language: English
- Copyright: © Academic Press 2023
- Published: April 1, 2023
- Imprint: Academic Press
- Hardcover ISBN: 9780443194184
About the Serial Volume Editors
Joseph Landry
Joseph Landry works at Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Affiliations and Expertise
Institute of Molecular Medicine, Virginia Commonwealth University, VA, USA
Swadesh Das
Dr. Swadesh Das works at Massey Cancer Center, Richmond, Virginia, USA.
Affiliations and Expertise
Massey Cancer Center, Richmond, VA, USA
Paul Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and Expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA
Ratings and Reviews
There are currently no reviews for "Epigenetic Regulation of Cancer in Response to Chemotherapy"